Diane E. Wilfong - Apr 5, 2024 Form 4 Insider Report for IPI Legacy Liquidation Co (IMPLQ)

Role
Director
Signature
/s/ Diane E. Wilfong
Stock symbol
IMPLQ
Transactions as of
Apr 5, 2024
Transactions value $
$0
Form type
4
Date filed
4/9/2024, 04:20 PM
Previous filing
Jun 20, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPLQ Stock Option (right to buy) Other $0 -31.4K -100% $0.00* 0 Apr 5, 2024 Common Stock 31.4K $8.02 Direct F1, F2
transaction IMPLQ Stock Option (right to buy) Other $0 -11.5K -100% $0.00* 0 Apr 5, 2024 Common Stock 11.5K $9.96 Direct F1, F2
transaction IMPLQ Stock Option (right to buy) Other $0 -12.8K -100% $0.00* 0 Apr 5, 2024 Common Stock 12.8K $8.65 Direct F1, F2
transaction IMPLQ Stock Option (right to buy) Other $0 -13.2K -100% $0.00* 0 Apr 5, 2024 Common Stock 13.2K $1.34 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Diane E. Wilfong is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the First Amended Joint Plan of Liquidation of Impel Pharmaceuticals Inc., which was confirmed by the United States Bankruptcy Court for the Northern District of Texas on April 2, 2024, all of the Issuer's shares of its capital stock were canceled and extinguished effective April 5, 2024, and any rights of any holder in respect thereof were canceled without any recovery.
F2 The option was fully vested.
F3 The option was scheduled to vest in full as of June 16, 2024.